Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company that is focused on the discovery, development, and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases.
Capricor’s innovative technology builds upon a large body of scientific research and enables them to approach the treatment of diseases in novel ways. The company is a leader in the field of exosome science.
Capricor’s lead candidate is CAP-1002. This “off-the-shelf” cardiac cell therapy is currently in clinical development for the treatment of Duchenne muscular dystrophy (DMD) and COVID-19.
CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a unique population of cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications. They have been administered to approximately 200+ human subjects throughout multiple clinical trials.
Capricor studies have been showing that exosome technology is significantly active in several disease models. The company is developing its exosome technologies as a next generation platform in a variety of diseases.